NasdaqCM:ACHVBiotechs
A Look at Achieve Life Sciences's Valuation After Rare FDA Priority Voucher for Nicotine Vaping Therapy
Achieve Life Sciences (ACHV) just made headlines after receiving a rare FDA Commissioner's National Priority Voucher for cytisinicline, its investigational treatment aimed at nicotine vaping cessation. This move significantly shortens the expected FDA review timeline.
See our latest analysis for Achieve Life Sciences.
News of the expedited review for cytisinicline has ignited momentum. Achieve Life Sciences' share price soared by over 36% in just one day, with a 42% gain over the past month...